Protagonist Therapeutics (MEX:PTGX) Cyclically Adjusted FCF per Share: MXN-19.90 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PTGX Protagonist Therapeutics Inc MEX:PTGX
47 GF Score
Price MXN1,565.33
GF Value MXN776.69
! 8 Warning Signs
View Full Analysis

What is Protagonist Therapeutics Cyclically Adjusted FCF per Share?

Protagonist Therapeutics MEX:PTGX 47 Cyclically Adjusted FCF per Share is MXN-19.90 as of Mar. 2026. GuruFocus rates MEX:PTGX with a GF Score™ of 47/100 and a GF Value™ of MXN776.69. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Protagonist Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was MXN-12.575. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN-19.90 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-27), Protagonist Therapeutics's current stock price is MXN1565.33. Protagonist Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was MXN-19.90. Protagonist Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Protagonist Therapeutics  (MEX:PTGX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Protagonist Therapeutics Cyclically Adjusted FCF per Share Related Terms


Protagonist Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Protagonist Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagonist Therapeutics Cyclically Adjusted FCF per Share Chart

Protagonist Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -24.55

Protagonist Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -25.96 -24.55 -19.90

MEX:PTGX vs CRNX, SYRE, TGTX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Protagonist Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagonist Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Protagonist Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


MEX:PTGX
47GF Score
Protagonist Therapeutics Inc MEX:PTGX
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagonist Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Protagonist Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-12.575/330.2130*330.2130
=-12.575

Current CPI (Mar. 2026) = 330.2130.

Protagonist Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -9.178 241.018 -12.575
201609 -15.946 241.428 -21.810
201612 -11.999 241.432 -16.411
201703 -11.684 243.801 -15.825
201706 -13.602 244.955 -18.336
201709 43.475 246.819 58.164
201712 -13.795 246.524 -18.478
201803 -13.206 249.554 -17.474
201806 -14.330 251.989 -18.778
201809 -7.694 252.439 -10.064
201812 -8.271 251.233 -10.871
201903 -13.434 254.202 -17.451
201906 2.164 256.143 2.790
201909 -10.207 256.759 -13.127
201912 -9.902 256.974 -12.724
202003 -13.530 258.115 -17.309
202006 -15.211 257.797 -19.484
202009 -9.668 260.280 -12.266
202012 -9.530 260.474 -12.082
202103 -13.356 264.877 -16.650
202106 -10.737 271.696 -13.050
202109 -12.313 274.310 -14.822
202112 -11.555 278.802 -13.686
202203 -15.495 287.504 -17.797
202206 -5.711 296.311 -6.364
202209 -10.389 296.808 -11.558
202212 -12.549 296.797 -13.962
202303 -12.245 301.836 -13.396
202306 -7.976 305.109 -8.632
202309 -7.951 307.789 -8.530
202312 4.759 306.746 5.123
202403 -7.221 312.332 -7.634
202406 80.265 314.175 84.362
202409 -9.129 315.301 -9.561
202412 -9.251 315.605 -9.679
202503 40.556 319.799 41.877
202506 -8.773 322.561 -8.981
202509 -0.582 324.800 -0.592
202512 -10.437 324.054 -10.635
202603 -12.575 330.213 -12.575

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN-19.90 mean?
Protagonist Therapeutics (MEX:PTGX) has a Cyclically Adjusted FCF per Share of MXN-19.90 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Protagonist Therapeutics and its competitors.
Is Protagonist Therapeutics' Cyclically Adjusted FCF per Share too high?
Protagonist Therapeutics' current Cyclically Adjusted FCF per Share is MXN-19.90. Overall, Protagonist Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Cyclically Adjusted FCF per Share compare to CRNX and SYRE?
Protagonist Therapeutics' Cyclically Adjusted FCF per Share of MXN-19.90 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Protagonist Therapeutics and its competitors. Protagonist Therapeutics's current Cyclically Adjusted FCF per Share is MXN-19.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Protagonist Therapeutics (MEX:PTGX) has a current Cyclically Adjusted FCF per Share of MXN-19.90. The stock's GF Value™ is MXN776.69, compared to a current price of MXN1,565.33 — trading 101.5% above its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN-19.90. Protagonist Therapeutics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Protagonist Therapeutics (MEX:PTGX), the current Cyclically Adjusted FCF per Share is MXN-19.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protagonist Therapeutics (MEX:PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of MXN1,565.33 is trading 101.5% above its estimated GF Value™ of MXN776.69.

Key valuation signals for MEX:PTGX:

  • Cyclically Adjusted FCF per Share: MXN-19.90
  • GF Value™: MXN776.69 vs. price of MXN1,565.33 (101.5% above fair value)
  • GF Score™: 47/100 with 8 warning signs

No single metric tells the full story. See the MEX:PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Protagonist Therapeutics Business Description

Other Exchanges PTGX:USA
Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
47GF Score

Get the complete analysis for MEX:PTGX

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,565.33
Price
MXN776.69
GF Value